Previous clinical studies have reported a mixed benefit of the combination of AI with EGFR or ERBB2 blockade in primary or naive advanced BC, and in some cases have shown a trend towards poorer outcome [25, 26]. This evidence concerns the gene EGFR and breast cancer.